European commission approves forxiga (dapagliflozin) for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adults.
PRESS RELEASE
(dapagliflozin) to include the treatment of symptomatic chronic heart failure (HF) with reduced ejection fraction (HFrEF) in adults.1,2 The approval by the EC is based on the positive results from the landmark DAPA-HF Phase III trial, published in The New England Journal of Medicine.5 It follows the recommendation for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency.